American Cutaneous Leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-Methilglucamine Antimoniate plus Pentoxifylline

    loading  Checking for direct PDF access through Ovid


SummaryBackgroundAmerican cutaneous leishmaniasis is characterized by single or multiple ulcerations. Cytokines, among other factors, have been shown to influence lesion development and tumoral necrosis factor-alpha is a major cytokine implicated in pathogenesis of ulcers.ObservationsWe tested oral pentoxifylline, a known tumoral necrosis factor-alpha inhibitor, at doses of 400 mg (2–3x/day), associated to N-methylglucamine antimoniate (15 mg/kg/day) in two patients with American cutaneous leishmaniasis unresponsive to antimonial drugs. We observed a satisfactory response with quick cure of skin lesions of these patients.ConclusionsOur results suggest that oral pentoxifylline in association to N-methylglucamine antimoniate should be consider in refractory cutaneous leishmaniasis patients.

    loading  Loading Related Articles